Myriad Genetics, Inc.

MYGN

HealthcareMedical - Diagnostics & ResearchNASDAQ

$4.29

Market Cap: $405.18M

Myriad Genetics, Inc. (MYGN) Valuation Summary

Updated May 10, 2026 23:23

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$1.46 – $40.39	$12.42	+189.6%
Revenue DCF 10Y	$1.98 – $41.51	$13.11	+205.6%
▸ Trading Multiples
EV/Revenue	$10.60 – $49.98	$24.90	+480.5%

Valuation History

DCF Analysis

Myriad Genetics, Inc. (MYGN) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$13.11

Market Price

$4.29

Upside / Downside

+205.6%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -8.2% to a target of 13.2% over 5 years, discounted at a WACC of 7.7%, Myriad Genetics, Inc. (MYGN) has an intrinsic value of $13.11 per share (range: $1.98 – $41.51).

Key Assumptions

Current Operating Margin

-8.2%

Target Operating Margin

13.2%

WACC

7.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

4.9%

Target CapEx/Rev

9.7%

D&A/Revenue

6.5%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	865	4.9%	-3.9%	-34	-34	56	(46)	1	-25	-24
2027	911	5.4%	0.3%	3	2	59	(53)	6	2	2
2028	964	5.8%	4.6%	45	35	62	(61)	7	29	24
2029	1,033	7.1%	8.9%	92	73	67	(70)	9	60	46
2030	1,036	0.3%	13.2%	137	108	67	(76)	0	99	71
2031	1,080	4.3%	13.2%	142	113	70	(84)	6	92	61
2032	1,123	4.0%	13.2%	148	117	73	(93)	6	91	56
2033	1,166	3.8%	13.2%	154	121	75	(102)	6	89	51
2034	1,206	3.5%	13.2%	159	126	78	(111)	6	87	46
2035	1,246	3.3%	13.2%	164	130	81	(121)	5	84	42

Enterprise Value Bridge

Sum of PV(FCFF)375

Terminal Value (Gordon Growth at 3.0%)1,839

PV of Terminal Value908

Enterprise Value1,283

(–) Net Debt60

Equity Value1,223

(÷) Shares Outstanding93

Fair Value per Share$13.11

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
5.7%	$7	$15	$24	$33	$42
6.7%	$5	$11	$17	$23	$30
7.7%	$3	$8	$13	$18	$23
8.7%	$3	$7	$11	$14	$18
9.7%	$2	$5	$9	$12	$15

Current price: $4.29. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 13.5% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Myriad Genetics, Inc. (MYGN) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$12.42

Market Price

$4.29

Upside / Downside

+189.6%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-8.2%

Target Operating Margin

13.2%

WACC

7.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

4.9%

Target CapEx/Rev

9.7%

D&A/Revenue

6.5%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	865	4.9%	-3.9%	-34	-34	56	(51)	1	-29	-28
2027	911	5.4%	0.3%	3	2	59	(62)	6	-7	-6
2028	964	5.8%	4.6%	45	35	62	(75)	7	15	13
2029	1,033	7.1%	8.9%	92	73	67	(90)	9	40	31
2030	1,036	0.3%	13.2%	137	108	67	(101)	0	74	53

Enterprise Value Bridge

Sum of PV(FCFF)62

Terminal Value (Gordon Growth at 3.0%)1,617

PV of Terminal Value1,157

Enterprise Value1,219

(–) Net Debt60

Equity Value1,159

(÷) Shares Outstanding93

Fair Value per Share$12.42

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
5.7%	$7	$15	$24	$32	$40
6.7%	$4	$10	$16	$23	$29
7.7%	$3	$8	$12	$17	$22
8.7%	$2	$6	$10	$14	$18
9.7%	$1	$5	$8	$11	$14

Current price: $4.29. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 13.5% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$24.90

Market Price

$4.29

Upside / Downside

+480.5%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Myriad Genetics, Inc. (MYGN) has a fair value of $24.90 based on 10 comparable companies in the Medical - Diagnostics & Research industry.

EV/Revenue Valuation — Medical - Diagnostics & Research

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Myriad Genetics, Inc.MYGN	400	0.6x	0.5x
Vir Biotechnology, Inc.VIR	1,495	21.1x	10.5x
Maravai LifeSciences Holdings, Inc.MRVI	1,333	6.2x	5.6x
CareDx, IncCDNA	1,127	2.8x	3.3x
AMN Healthcare Services, Inc.AMN	1,120	0.7x	0.6x
Castle Biosciences, Inc.CSTL	601	1.5x	1.5x
Ginkgo Bioworks Holdings, Inc.DNA	582	4.9x	4.8x
Personalis, Inc.PSNL	532	5.7x	6.2x
Evolent Health, Inc.EVH	477	0.7x	0.5x
Fulgent Genetics, Inc.FLGT	453	1.3x	1.5x
DarioHealth Corp.DRIO	57	2.8x	2.4x
Industry Median		2.8x	2.8x
(*) Revenue		825	865
= Enterprise Value		2,327	2,441
(-) Net Debt		60	60
Equity Value		2,266	2,381
(/) Outstanding shares		93	93
Fair Price		$24	$26

Selected Fair Value (avg of trailing + forward)

$24.90

+480.5%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$1.46 – $40.39

$12.42

+189.6%

Revenue DCF 10Y

$1.98 – $41.51

$13.11

+205.6%

▸ Trading Multiples

EV/Revenue

$10.60 – $49.98

$24.90

+480.5%

DCF Analysis

Myriad Genetics, Inc. (MYGN) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$13.11

Market Price

$4.29

Upside / Downside

+205.6%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-8.2%

Target Operating Margin

13.2%

WACC

7.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

4.9%

Target CapEx/Rev

9.7%

D&A/Revenue

6.5%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	865	4.9%	-3.9%	-34	-34	56	(46)	1	-25	-24
2027	911	5.4%	0.3%	3	2	59	(53)	6	2	2
2028	964	5.8%	4.6%	45	35	62	(61)	7	29	24
2029	1,033	7.1%	8.9%	92	73	67	(70)	9	60	46
2030	1,036	0.3%	13.2%	137	108	67	(76)	0	99	71
2031	1,080	4.3%	13.2%	142	113	70	(84)	6	92	61
2032	1,123	4.0%	13.2%	148	117	73	(93)	6	91	56
2033	1,166	3.8%	13.2%	154	121	75	(102)	6	89	51
2034	1,206	3.5%	13.2%	159	126	78	(111)	6	87	46
2035	1,246	3.3%	13.2%	164	130	81	(121)	5	84	42

Enterprise Value Bridge

Sum of PV(FCFF)375

Terminal Value (Gordon Growth at 3.0%)1,839

PV of Terminal Value908

Enterprise Value1,283

(–) Net Debt60

Equity Value1,223

(÷) Shares Outstanding93

Fair Value per Share$13.11

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
5.7%	$7	$15	$24	$33	$42
6.7%	$5	$11	$17	$23	$30
7.7%	$3	$8	$13	$18	$23
8.7%	$3	$7	$11	$14	$18
9.7%	$2	$5	$9	$12	$15

Current price: $4.29. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 13.5% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$24.90

Market Price

$4.29

Upside / Downside

+480.5%

Verdict

Undervalued

EV/Revenue Valuation — Medical - Diagnostics & Research

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Myriad Genetics, Inc.MYGN	400	0.6x	0.5x
Vir Biotechnology, Inc.VIR	1,495	21.1x	10.5x
Maravai LifeSciences Holdings, Inc.MRVI	1,333	6.2x	5.6x
CareDx, IncCDNA	1,127	2.8x	3.3x
AMN Healthcare Services, Inc.AMN	1,120	0.7x	0.6x
Castle Biosciences, Inc.CSTL	601	1.5x	1.5x
Ginkgo Bioworks Holdings, Inc.DNA	582	4.9x	4.8x
Personalis, Inc.PSNL	532	5.7x	6.2x
Evolent Health, Inc.EVH	477	0.7x	0.5x
Fulgent Genetics, Inc.FLGT	453	1.3x	1.5x
DarioHealth Corp.DRIO	57	2.8x	2.4x
Industry Median		2.8x	2.8x
(*) Revenue		825	865
= Enterprise Value		2,327	2,441
(-) Net Debt		60	60
Equity Value		2,266	2,381
(/) Outstanding shares		93	93
Fair Price		$24	$26

Selected Fair Value (avg of trailing + forward)

$24.90

+480.5%